Beam Doses First Patient in BEAM-302 Global Pivotal Trial; Reports Q1
Beam Therapeutics dosed the first patient in the global pivotal cohort of its BEAM-302 trial for AATD and reported $1.2 billion in cash, indicating continued clinical progress and operational strength.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day